A novel STAT3 inhibitor, HJC0152, exerts potent antitumor activity in glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Aberrant signal transducer and activator of transcription 3 (STAT3) activation is linked to glioblastoma development and poor patient outcomes.
• STAT3 is a potential therapeutic target, but approved inhibitors are limited.
• HJC0152 is a novel, orally active small-molecule compound designed to inhibit STAT3 activity.

Purpose of the Study:

• To evaluate the efficacy of HJC0152 against glioblastoma.
• To determine HJC0152's effects on glioblastoma cell growth, proliferation, and chemosensitivity.
• To assess HJC0152's impact on glioblastoma xenograft tumor growth.

Main Methods:

• Investigated HJC0152's mechanism of action, specifically its effect on STAT3 phosphorylation at Tyr705.
• Conducted in vitro studies using glioblastoma cell lines to assess proliferation, motility, apoptosis, and chemosensitivity.
• Performed in vivo studies using glioblastoma xenograft models to evaluate tumor growth inhibition.

Main Results:

• HJC0152 effectively inhibited STAT3 phosphorylation at Tyr705, leading to STAT3 inactivation.
• In vitro, HJC0152 suppressed glioblastoma cell proliferation and motility, induced apoptosis, and increased sensitivity to chemotherapy.
• In vivo, HJC0152 demonstrated significant inhibition of glioblastoma xenograft tumor growth.

Conclusions:

• HJC0152 exhibits potent anti-glioblastoma activity through STAT3 inhibition.
• The compound demonstrates efficacy both in vitro and in vivo, suppressing tumor growth and enhancing chemosensitivity.
• HJC0152 represents a promising candidate for developing novel STAT3-targeting therapies for human glioblastoma.